Laval, Quebec, located in the greater Montréal area, is the site for Boehringer Ingelheim (Canada) Ltd./Ltée International Center of Excellence for Virology.
In our Laval pharmaceutical research center, over 150 researchers trained in a wide range of disciplines supported by a strong support group and backed by extensive investments in technology, investigate and develop potential drugs for life-threatening viral diseases, principally HIV and HCV.
Our Laval team is uniquely focused on developing molecules that can make a significant difference in the lives of people infected with potentially lethal viruses.